Adicet Bio, Inc. announced its financial results for Q4 and the year ended December 31, 2025, highlighting strong enrollment in its Phase 1 autoimmune program and regulatory alignment with the FDA for outpatient dosing. The company expects continued momentum in clinical trials.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.